The Medicare Drug Price Negotiation Program has acquired something it did not previously have: a permanent regulatory framework governing its operations from 2029 onward.
On November 5, 2026, the Centers for Medicare & Medicaid Services issued final rule CMS-4215-F, codifying major parts of a program that had operated through guidance documents during its first three negotiation cycles.
The rule appeared in the Federal Register on November 9 and takes effect on December 5, 2026. Its principal provisions apply to negotiated drug prices effective in 2029 and later years.
That does not mean CMS invented the program or permanently insulated it from future political changes. Congress created Medicare drug price negotiation through the Inflation Reduction Act of 2022.
What CMS has done is replace much of the temporary administrative machinery with regulations intended to govern future negotiation cycles.
For the pharmaceutical industry, that distinction matters. Guidance can be revised administratively. Regulations involve a more formal rulemaking process, although future administrations and Congress retain the power to change the framework.
For the obesity market, the timing is particularly consequential.
On January 1, 2027, semaglutide, the active ingredient in Ozempic, Wegovy and Rybelsus, becomes subject to its negotiated Medicare maximum fair price.
CMS has published a standardized negotiated figure of $274 for a 30-day supply, approximately 71% below the $959 historical list-price benchmark used in its comparison.
The new rule does not establish that price. It was agreed upon in an earlier negotiation cycle.
Instead, CMS-4215-F addresses the rules that determine which drugs qualify for future negotiation, how existing prices may be renegotiated and whether certain modified combination products can inherit an older drug’s negotiation history.
That final question generated some of the sharpest industry objections.
But the language CMS adopted is narrower than a general restriction on combination therapies.
What the Medicare Drug Price Negotiation Program Rule Actually Does
The Medicare Drug Price Negotiation Program was established by the Inflation Reduction Act, signed into law in August 2022.
The law authorized CMS to negotiate maximum fair prices, or MFPs, for selected high-expenditure prescription medicines and biological products that meet statutory eligibility requirements.
The program began with ten Medicare Part D drugs whose negotiated prices took effect in 2026.
A second group of fifteen Part D drugs received negotiated prices effective in 2027, while another fifteen drugs were selected for prices beginning in 2028.
For those first three price years, Congress directed CMS to implement the program through program instructions and guidance rather than the ordinary regulatory framework.
That temporary implementation authority expires after 2028.
CMS-4215-F establishes regulations for subsequent years and makes those provisions applicable, where specified, to drugs selected during earlier cycles once the 2029 framework begins.
CMS received approximately 11,330 timely public comment letters in response to the proposed rule.
The final version covers drug selection, manufacturer agreements, negotiation methodology, publication of agreed prices, renegotiation, eligibility determinations and certain Medicare Part D payment requirements.
It also establishes a new approach to specific combination-drug formulations.
Under the program, CMS identifies eligible drugs using criteria that include Medicare spending, the availability of generic or biosimilar competition and the period since FDA approval or licensure.
A medicine does not become eligible simply because it is expensive.
CMS must apply the statutory selection criteria, rank eligible medicines and identify which products fall within the permitted number of selections for a given cycle.
For the fourth negotiation cycle, CMS will select up to twenty additional drugs covered under Medicare Part D, payable under Part B, or both.
The agency must publish its selection list by February 1, 2027. The negotiated prices from that cycle will begin in 2029.
Participating manufacturers must execute negotiation agreements by the statutory deadline of February 28 following selection.
Once a drug has an agreed maximum fair price in effect, that price continues to apply during the relevant price applicability period unless the drug is removed from the program or the applicable price changes under the rules.
One important route out of the program involves genuine market competition.
CMS must determine not only that an appropriate generic has been approved or a biosimilar licensed, but also that it is subject to what the agency calls bona fide marketing.
Approval without qualifying commercial availability does not automatically end a selected drug’s negotiated-price status.
That distinction is important because a nominal generic approval and meaningful competition in the market are not necessarily the same thing.
The negotiation program was already law. The November rule establishes the administrative structure intended to govern it from 2029 onward.
Semaglutide’s Medicare Price Was Already Negotiated
The most visible connection between Medicare negotiation and obesity medicines is semaglutide.
Novo Nordisk markets the molecule through several products, including Ozempic for type 2 diabetes and other approved indications, Wegovy for chronic weight management and additional approved indications, and Rybelsus as an oral formulation.
CMS selected semaglutide during the second negotiation cycle and published its agreed maximum fair price in November 2025.
The agency’s standardized comparison placed the 30-day negotiated price at $274, against a 2024 wholesale acquisition cost benchmark of $959.
That represents a 71% reduction against the historical list-price figure.
But the comparison requires several qualifications.
First, the $959 figure is a manufacturer list-price benchmark, not the average amount Medicare actually paid after rebates or other price concessions.
Second, the $274 figure is a standardized negotiated amount used to communicate the result across semaglutide products.
The applicable maximum fair prices vary by dosage form and package.
Published analyses of CMS pricing data place a typical Ozempic pen and a 30-tablet Rybelsus supply at approximately $277, while four Wegovy pens are approximately $386.
Those values illustrate why the reported $274 should not be treated as the exact price of every semaglutide prescription.
Third, the maximum fair price is not the amount every Medicare beneficiary will pay at the pharmacy counter.
Patient cost sharing depends on the applicable benefit rules, coverage arrangements and individual circumstances.
There is also a separate voluntary pricing arrangement that has sometimes been discussed alongside the statutory negotiation program.
Novo Nordisk and Eli Lilly agreed to pricing terms associated with CMS initiatives intended to expand access to selected GLP-1 medicines.
Those arrangements include a reported $245 net-price benchmark per 30-day supply for eligible products under the voluntary model framework.
That is not the same price mechanism as the statutory $274 maximum fair price.
CMS also operates the Medicare GLP-1 Bridge, a demonstration arrangement intended to provide eligible beneficiaries with access to certain medicines outside the ordinary Part D benefit payment flow.
Eligible participants in that program have a separate $50 copayment, and eligibility restrictions apply.
The Bridge has been extended through December 31, 2027, while the broader BALANCE Model’s Medicare implementation schedule remains subject to program decisions.
These programs may involve the same medicines, but their prices serve different purposes.
Combining the statutory negotiated price, a voluntary net-price agreement and a patient’s copayment into a single headline would obscure those differences.
Grey Pepper previously examined related pricing issues in our analysis of Medicare negotiation and official drug-price statistics.
The important point for CMS-4215-F is simpler.
The new regulation does not renegotiate semaglutide or alter its previously published 2027 maximum fair price.
It establishes the framework through which future selection, renegotiation and qualifying product changes will be handled.
The Combination-Drug Clause Is Narrower Than the Industry Debate Suggests
Among the most contested provisions of CMS-4215-F is its treatment of certain fixed combination drugs.
The concern is that a manufacturer could potentially move patients from an older medicine to a newly formulated version and avoid the negotiated price associated with the original product.
Consider a biological medicine originally administered through an intravenous infusion.
A company later develops a formulation that includes an additional active ingredient enabling the medicine to be administered subcutaneously.
The formulation may offer patients a meaningful improvement in convenience or administration time.
But under the previous general approach to fixed combination products, adding another active ingredient could also result in the new product being treated as a distinct drug for negotiation purposes.
That might create a new eligibility timeline even if much of the underlying therapeutic substance remained the same.
CMS considers that a potential program-integrity problem.
Its final rule addresses a specific category of products that contain a shared active ingredient but differ because an additional ingredient creates a new formulation and enables an alternative route of administration.
The products must also meet requirements concerning the identity of the New Drug Application or Biologics License Application holder.
The example repeatedly discussed by CMS involves hyaluronidase.
Hyaluronidase can be added to certain biological products to enable subcutaneous administration of medicines that were previously delivered intravenously.
Under the new policy, an eligible product containing an original active ingredient plus hyaluronidase may be grouped with the original product as a single qualifying drug for negotiation purposes.
If that drug is selected, the agreed maximum fair price may apply to the relevant formulations and strengths under the program’s requirements.
The Federal Register provides an illustrative scenario in which such a formulation could otherwise have a separate negotiation timeline extending to 2039, rather than potentially being included in a 2029 negotiated-price period.
That is an illustration of how the rule can operate, not a finding that every reformulated drug will be selected for negotiation in 2029.
The distinction becomes even more important when considering the industry’s objections.
Pharmaceutical manufacturers and trade associations raised concerns that the policy could discourage the development of improved drug-delivery systems.
A formulation that permits an easier injection instead of an intravenous infusion can require additional research, manufacturing development, clinical studies and regulatory review.
Critics argued that grouping such formulations with an older product could reduce the financial incentive to invest in those improvements.
CMS acknowledged those concerns but retained the provision, arguing that the policy was necessary to avoid undermining the statutory treatment of different formulations of a qualifying single-source drug.
Crucially, CMS also emphasized the limits of its decision.
The Federal Register states that the provision does not apply to other kinds of fixed combination drugs that fail to meet its specific criteria.
That means the rule should not be summarized as automatically treating every medicine containing two active drugs as a single product for Medicare negotiation.
The provision targets a particular route-changing reformulation. It is not a blanket rule against combining two medicines.
The distinction is important for the incretin industry.
Novo Nordisk’s investigational CagriSema combines the GLP-1 receptor agonist semaglutide with cagrilintide, an amylin analog.
Those ingredients are intended to provide complementary pharmacological activity rather than merely enable an alternative administration route for an existing drug.
On that basis, CagriSema does not obviously meet the particular route-changing formulation criteria described by CMS.
But that is a reading of the published rule, not a formal CMS determination concerning CagriSema or any other specific incretin combination.
The agency will need to apply the regulatory language to individual products and their approval structures as relevant cases arise.
For now, the strongest conclusion is narrower than either a general industry exemption or a blanket prohibition.
CMS has closed a specific potential route around drug-price negotiation while leaving other types of combination products subject to the program’s existing eligibility framework.
Small Biotechs, Pharmacy Reimbursement and Renegotiation
The final rule also includes provisions that received less public attention but may matter to drug manufacturers, Medicare plans and pharmacies.
One concerns qualifying small biotechnology medicines.
The Inflation Reduction Act originally provided a temporary exemption from selection for certain small biotech drugs during the 2026, 2027 and 2028 price years.
That exclusion is scheduled to end.
For 2029 and 2030, however, qualifying small biotech drugs receive a separate temporary price floor as provided by statute.
The floor is generally calculated using 66% of the applicable 2021 average non-federal average manufacturer price, with specified adjustments and alternative calculations where required.
CMS cannot offer or agree to a negotiated price below the applicable statutory floor for qualifying products.
This does not mean small biotechnology medicines are permanently excluded from the negotiation program.
The provision creates a limited protection during specified price years, with eligibility and calculation rules that manufacturers must satisfy.
Another important issue involves pharmacies.
The rule codifies statutory requirements that Medicare Part D plans include covered selected drugs with an effective maximum fair price on their formularies, subject to applicable formulary rules.
It also provides that the negotiated price used for payment by a Part D plan for a selected drug must not exceed the applicable maximum fair price plus any dispensing fees.
But a maximum permitted payment is not the same as a guaranteed minimum reimbursement.
Pharmacy stakeholders urged CMS to address concerns about dispensing fees and compensation when pharmacies supply medicines subject to negotiated prices.
Some commenters requested a minimum dispensing fee, while others sought protections involving pharmacy service fees and other reimbursement practices.
CMS declined to establish new dispensing-fee requirements in this final rule.
The agency said it expects plans and pharmacy benefit managers to engage in sustainable and fair reimbursement practices and will continue monitoring pharmacy compensation.
That leaves a practical question unresolved.
A medicine may have a substantially lower negotiated price, but pharmacy access also depends on acquisition costs, dispensing compensation and the commercial terms between plans, pharmacy benefit managers and dispensing entities.
Lower prices do not automatically guarantee that every pharmacy can supply every selected medicine under financially sustainable terms.
The final rule also addresses renegotiation.
A drug’s first maximum fair price is not necessarily the last negotiated price it will receive.
CMS can select certain qualifying drugs for renegotiation when the statutory criteria are satisfied.
For the 2029 and later price years, the agency has finalized rules governing how it identifies eligible products, gathers information and conducts renegotiation.
CMS will also consider the previously agreed maximum fair price among the relevant factors when evaluating a drug selected for renegotiation.
That creates an explicit connection between the original negotiated price and later price-setting discussions.
It does not establish that every previously negotiated medicine will automatically receive a new price.
CMS must first determine eligibility and selection under the applicable requirements.
The agency has indicated that drugs may be selected for renegotiation during the next cycle, but individual future selections are not established by the November final rule itself.
What the Rule Means for GLP-1 Pricing After 2027
For pharmaceutical companies, CMS-4215-F introduces greater regulatory clarity about how the Medicare Drug Price Negotiation Program will operate in later years.
For investors and manufacturers developing obesity treatments, the practical significance lies in product life cycles.
Clinical development does not stop when a medicine first reaches the market.
Companies frequently investigate new strengths, dosage forms, administration routes, combination therapies and additional medical indications.
Those decisions can influence revenue, patient access and the timing of generic or biosimilar competition.
Medicare’s rules for determining which formulations belong to the same qualifying drug therefore matter beyond the first approval.
They can influence whether a newly introduced version receives its own negotiation timeline or remains associated with an older product for pricing purposes.
But the November final rule should not be treated as a broad determination about the future of every GLP-1 combination product.
The new fixed-combination provision applies only when its specific criteria are met.
Similarly, CMS has not announced a newly negotiated price for an obesity drug through CMS-4215-F.
Semaglutide’s previously announced price becomes effective in January 2027, independently of the 2029 regulatory framework.
Its eventual effect on spending will depend on actual utilization, product mix, coverage arrangements, beneficiary cost sharing and the interaction between statutory negotiation and separate voluntary pricing initiatives.
For employers and commercial insurers, Medicare’s published prices may provide another reference point in negotiations and benefit planning.
But they do not directly control prices in private insurance markets.
Grey Pepper previously examined those pressures in our analysis of employer GLP-1 coverage costs for 2027.
Even within Medicare, price and coverage remain separate questions.
A negotiated maximum fair price does not by itself establish that a drug is covered for every condition or that every beneficiary meets the criteria to receive it.
Those distinctions are particularly important for obesity treatments because Medicare’s coverage rules, approved indications and demonstration programs affect which patients can obtain a medicine.
The next immediate milestone for the negotiation program is February 1, 2027, when CMS must identify the drugs selected for the 2029 price year.
That list will provide a clearer indication of which medicines face a new round of statutory pricing negotiations.
Until then, the November rule’s significance is institutional rather than product-specific.
It codifies the selection process, formalizes renegotiation procedures, clarifies the treatment of certain new formulations and carries forward requirements governing the relationship between maximum fair prices and Medicare Part D.
It also leaves meaningful questions unresolved, including pharmacy reimbursement practices, the future application of the combination-drug provision and the commercial consequences of negotiated prices.
Those questions will be answered through future CMS decisions, product-specific determinations, industry responses and potential legal challenges.
The most significant development is not that Medicare suddenly acquired the authority to negotiate drug prices.
It already had that authority.
What changed in November 2026 was the regulatory architecture intended to govern how that authority operates in the years ahead.
For GLP-1 manufacturers, the question is no longer whether Medicare negotiation exists. It is how the program will treat a medicine as its formulations, competitors and commercial life cycle change.
Sources and Further Reading
- Centers for Medicare & Medicaid Services. CMS Final Rule Strengthens, Supports Lasting Drug Savings. November 5, 2026.
- CMS. Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program Final Rule (CMS-4215-F): Official Fact Sheet. November 5, 2026.
- Federal Register. Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program. 91 FR 72176, November 9, 2026. Effective December 5, 2026.
- CMS. Selected Drugs and Negotiated Prices: Initial Price Applicability Year 2027.
- CMS. Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2027. November 2025.
- CMS. Medicare GLP-1 Bridge: Program Rules, Eligibility and Beneficiary Cost Sharing.
- KFF. What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid and the Medicare GLP-1 Bridge. May 11, 2026.
- Health Affairs Forefront. Beyond the Numbers: Insights From the 2027 Medicare Drug Price Negotiation Cycle.
